Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-Small-Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Istituto Clinco Humanitas

Rozzano, Mialno, 20089, Italy

About this study

DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Availability of tumor tissue or blood samples.
Diagnosis of NSCLC
At least one treatment with EGFR-TKIs inhibitors

Exclusion criteria

Other than NSCLC primary diagnosis
No treatment with EGFR-TKIs inhibitors
No archival tissue available

Treatment and study plan

Primary outcomes

to evaluate the presence of EGFR- and AKT-DNA polymorphisms.

Time frame: At the end of enrollment

Secondary outcomes

to correlate the biological characteristics with clinical characteristics and survival data of patients.

Time frame: At the end of enrollment

Sponsors and collaborators

Lead sponsor

Armando Santoro, MD

Other

Registry information

Official study title

Relationship of Polymorphisms and Mutations of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors Responsiveness in Non-small-cell Lung Cancer Patients

Important dates

Study start: 2008
Primary completion: 2011
Study completion: 2011
First posted: Jan 29, 2009
Registry last updated: Dec 2, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed